Brane Grambozov

Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

Zehentmayr, F. (Erstautor/-in), Ruznic, E. (Co-Autor/-in), Feurstein, P. (Co-Autor/-in), Langer, B. (Co-Autor/-in), Grambozov, B. (Co-Autor/-in), Klebermass, M. (Co-Autor/-in), Hochreiter, A. (Co-Autor/-in), Purevdorj, A. (Co-Autor/-in), Gruber, G. (Co-Autor/-in), Minasch, D. (Co-Autor/-in), Böhmer-Breitfelder, B. (Co-Autor/-in), Steffal, C. (Co-Autor/-in), Kirchhammer, K. (Co-Autor/-in), Stranzl, H. (Co-Autor/-in), Röder, F. (Co-Autor/-in) & Dieckmann, K. (Letztautor/-in), 25 Apr. 2025, in: Cancers.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

Immediate start of durvalumab after chemoradiotherapy in unresectable non-small cell lung cancer UICC stage III: early results from the TORG1937/DATE study

Grambozov, B. (Erstautor/-in), Stana, M. (Co-Autor/-in) & Zehentmayr, F. (Letztautor/-in), Jan. 2025, in: Journal of Thoracic Disease. 17, 1, S. 1-4 4 S.

Publikation: Beitrag in Fachzeitschrift › Letter to the editor › Begutachtung

Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

Ruznic, E. (Erstautor/-in), Klebermass, M. (Co-Autor/-in), Zellinger, B. (Co-Autor/-in), Langer, B. (Co-Autor/-in), Grambozov, B. (Co-Autor/-in), Purevdorj, A. (Co-Autor/-in), Karner, J. (Co-Autor/-in), Gruber, G. (Co-Autor/-in), Stana, M. (Co-Autor/-in), Minasch, D. (Co-Autor/-in), Kirchhammer, K., Steffal, C. (Co-Autor/-in), Stranzl, H. (Co-Autor/-in), Moosbrugger, R. (Co-Autor/-in), Feurstein, P. (Co-Autor/-in), Dieckmann, K. (Co-Autor/-in), Zehentmayr, F. (Letztautor/-in) & ALLSTAR Group, 1 Feb. 2025, in: Journal of Clinical Medicine. 14, 3, 16 S., 945.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

157P Durvalumab impacts progression-free survival but not local control in patients with inoperable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)

Zehentmayr, F., Feuerstein , P., Ruznic, E., Langer, B., Grambozov, B., Klebermass, M., Huepfel, H., Feichtinger, J., Minasch, D., Heilmann, M., Breitfelder, B., Steffal, C., Gastinger-Grass, G., Kirchhammer, K., Kazil, M., Stranzl, H. & Dieckmann, K., 2024, in: ESMO OPEN.

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

377: ESR/ATS Thresholds for DLCO Correlate with Radiation Dosimetry and Pneumonitis Rate in NSCLC III

Zehentmayr, F. (Letztautor/-in), Grambozov, B., Ruznic, E. (Erstautor/-in), Stana, M., Karner, J., Gaisberger, C., Zellinger, B., Moosbrugger, R., Fastner, G., Studnicka, M. & Sedlmayer, F., 2024, in: RADIOTHERAPY AND ONCOLOGY.

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung